This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n8http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F09%3A5822%21RIV10-MZ0-00064165/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F09%3A5822%21RIV10-MZ0-00064165
rdf:type
skos:Concept n8:Vysledek
dcterms:description
Myelodysplastic syndrome is one of the most frequent haematological diseases. Its incidence is on the rise due to the increasing life expectancy of the population and also probably due to the increasing exposure to various toxic substances. Treatment of this disease, though, remains difficult. In terms of therapy, we most frequently divide MDS into low and very high-risk patients. In our review, we deal with some of the novel therapeutic approaches and preparations used in the low risk patients, also taking into account that these should become available to our patients in the foreseeable future. We first focus on growth factors, especially erythropoiesis stimulating proteins, and the fundamentals of treatment based on current clinical trials and new preparations. We then present an overview of chelation therapy, including new guidelines and a brief summary of our own results and experience. Myelodysplastic syndrome is one of the most frequent haematological diseases. Its incidence is on the rise due to the increasing life expectancy of the population and also probably due to the increasing exposure to various toxic substances. Treatment of this disease, though, remains difficult. In terms of therapy, we most frequently divide MDS into low and very high-risk patients. In our review, we deal with some of the novel therapeutic approaches and preparations used in the low risk patients, also taking into account that these should become available to our patients in the foreseeable future. We first focus on growth factors, especially erythropoiesis stimulating proteins, and the fundamentals of treatment based on current clinical trials and new preparations. We then present an overview of chelation therapy, including new guidelines and a brief summary of our own results and experience Myelodysplastic syndrome is one of the most frequent haematological diseases. Its incidence is on the rise due to the increasing life expectancy of the population and also probably due to the increasing exposure to various toxic substances. Treatment of this disease, though, remains difficult. In terms of therapy, we most frequently divide MDS into low and very high-risk patients. In our review, we deal with some of the novel therapeutic approaches and preparations used in the low risk patients, also taking into account that these should become available to our patients in the foreseeable future. We first focus on growth factors, especially erythropoiesis stimulating proteins, and the fundamentals of treatment based on current clinical trials and new preparations. We then present an overview of chelation therapy, including new guidelines and a brief summary of our own results and experience
dcterms:title
Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome Novinky v terapii nízce rizikových nemocných s myelodysplastickým syndromem Novinky v terapii nízce rizikových nemocných s myelodysplastickým syndromem
skos:prefLabel
Novinky v terapii nízce rizikových nemocných s myelodysplastickým syndromem Novinky v terapii nízce rizikových nemocných s myelodysplastickým syndromem Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome
skos:notation
RIV/00064165:_____/09:5822!RIV10-MZ0-00064165
n3:aktivita
n12:N
n3:aktivity
N
n3:cisloPeriodika
2
n3:dodaniDat
n13:2010
n3:domaciTvurceVysledku
n14:7931360
n3:druhVysledku
n10:J
n3:duvernostUdaju
n16:S
n3:entitaPredkladatele
n11:predkladatel
n3:idSjednocenehoVysledku
330094
n3:idVysledku
RIV/00064165:_____/09:5822
n3:jazykVysledku
n4:cze
n3:klicovaSlova
myelodysplastic syndrome; growth factors; chelation therapy; hypomethylation agents; immunomodulation; immunosuppression
n3:klicoveSlovo
n5:growth%20factors n5:myelodysplastic%20syndrome n5:hypomethylation%20agents n5:immunomodulation n5:immunosuppression n5:chelation%20therapy
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[591E03D42ADF]
n3:nazevZdroje
Transfuze a hematologie dnes
n3:obor
n15:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
1
n3:rokUplatneniVysledku
n13:2009
n3:svazekPeriodika
15
n3:tvurceVysledku
Jonášová, Anna
s:issn
1213-5763
s:numberOfPages
7